Efficacy and Safety of New Treatments on Patients with Hepatitis C: Telaprevir and Boceprevir
Abstract Hepatitis C is a disease caused by a virus that may have different genotypes. The standard treatment of peginterferon plus ribavirin, is added boceprevir (BCP) or telaprevir (TVP), direct-acting antiviral agents. The aim of this study is to evaluate the effectiveness through and the safety through the side effects of drugs. This is an observational retrospective study conducted in patients with standard treatment BCP or TVP in 2012 at the Hospital of Leon. The sample of 27 patients, 7 of them stopped the treatment post lead-in. Of the remaining 20, 20% stopped it, 25% due to adverse reactions and 75% because of the HCV RNA or stopping rules. The remaining 80% (16 patients), 68.75% achieved sustained virologic response while 31.25% relapsed. It is appreciated a better response in relapsed patients with genotype 1a and phenotype CT. With respect to side effects, the most frequent were gastrointestinal disorders, rash, weight loss, neutropenia, anemia, thrombocytopenia and psychiatric disorders. The complexity of these treatments requires a multidisciplinary monitoring of patients.
- Referencias
- Cómo citar
- Del mismo autor
- Métricas
Agencia española de Medicamentos y Productos Sanitarios [internet]. Madrid: Agencia Española del Medicamento y Productos Sanitarios; 2011 [acceso 29 de abril de 2014]. Disponible en: http://www.aemps.es.
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16
Pellicer M, Lebrero A, Fernández-Pacheco M, Matoses SM, Herranz C, Luque R. Efectividad y seguridad del tratamiento de la hepatitis crónica c basado en triple terapia. Farm Hosp. 2013;37(Suppl 1): 178
Ubago Pérez R, Castillo Muñoz MA, Navarro Caballero JA, Márquez Peláez S. Inhibidores de la proteasa (boceprevir y telaprevir) en el tratamiento de pacientes monoinfectados por el VHC: eficacia, seguridad y eficiencia comparada [Internet]. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias, 2012. Informe 1/2012. URL: www.juntadeandalucia.es/salud/orgdep /AETSA
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16
Pellicer M, Lebrero A, Fernández-Pacheco M, Matoses SM, Herranz C, Luque R. Efectividad y seguridad del tratamiento de la hepatitis crónica c basado en triple terapia. Farm Hosp. 2013;37(Suppl 1): 178
Ubago Pérez R, Castillo Muñoz MA, Navarro Caballero JA, Márquez Peláez S. Inhibidores de la proteasa (boceprevir y telaprevir) en el tratamiento de pacientes monoinfectados por el VHC: eficacia, seguridad y eficiencia comparada [Internet]. Sevilla: Agencia de Evaluación de Tecnologías Sanitarias, 2012. Informe 1/2012. URL: www.juntadeandalucia.es/salud/orgdep /AETSA
Gonzalez, M., Gutierrez, E., Saez, M., Ortega, L., & Ortiz De Urbina, J. J. (2016). Efficacy and Safety of New Treatments on Patients with Hepatitis C: Telaprevir and Boceprevir. FarmaJournal, 1(2), 109–116. Retrieved from https://revistas.usal.es/cinco/index.php/2445-1355/article/view/13282
Most read articles by the same author(s)
- Pedro Gómez, María Asunción González, Aníbal Martín, Juan José Ortiz De Urbina, “Efficacy and safety of eltrombopag as thromboyetic agent in the treatment of immune thrombocytopenic purpura in patients that started treatment at Complejo Asistencial Universitario de León during the period 2012-2015 , FarmaJournal: Vol. 2 No. 2 (2017)
- Cristina Alvarez, Mónica Saez, Esperanza Gutierrez, Luis Ortega, Juan José Ortiz De Urbina, Study of Antimicrobial Use in a General Surgery Unit After Changes in the Hospital’s Formulary , FarmaJournal: Vol. 1 No. 2 (2016)
Downloads
Download data is not yet available.
+
−